PrEP: latest news

PrEP resources

PrEP features

PrEP news from aidsmap

  • Good adherence seen in study of intermittent PrEP

    The first results published from the IPERGAY study, a trial of pre-exposure prophylaxis (PrEP) in gay men taking place in France and Quebec, appear to indicate excellent adherence to a novel ‘pre-and-post’ intermittent PrEP strategy designed to save money ...

    11 hours ago | Gus Cairns
  • Overall PrEP effectiveness in iPrEx OLE study 50%, but 100% in those taking four or more doses a week

    The open-label extension of the iPrEx study of pre-exposure prophylaxis (iPrEx OLE) reported its main findings at the 20th International AIDS Conference (AIDS 2014) in Melbourne, Australia today, and published simultaneously in The Lancet. Recruitment, retention and adherence data were reported ...

    21 hours ago | Gus Cairns
  • European CDC cautious about PrEP

    The European Centre for Disease Prevention and Control (ECDC) has issued a paper saying that it cannot make a clear Europe-wide recommendation on the use of pre-exposure prophylaxis (PrEP), and that it would require clearer data on efficacy, cost-effectiveness, side-effects, ...

    18 July 2014 | Gus Cairns
  • High levels of adherence to study medication among women who conceived during HIV PrEP study

    HIV pre-exposure prophylaxis (PrEP) appears to be an acceptable strategy for safer conception for HIV-negative women in a relationship with an HIV-positive partner, according to the results of a study published in the online edition of ...

    14 July 2014 | Michael Carter
  • PrEP users say it provides an 'extra layer of protection' and 'peace of mind'

    American gay men who have chosen to take pre-exposure prophylaxis (PrEP) are aware of their own risk of being exposed to HIV and see PrEP as providing 'an extra layer of protection' on top of their efforts to ...

    12 June 2014 | Roger Pebody
  • Model shows potential for substantial long-term HIV risk for serodifferent couples, even with new prevention tools

    A mathematical model derived from current knowledge about the efficacy of various different prevention strategies has found that, based on these data, the risk of HIV transmission from a person living with HIV to an HIV-negative partner in a ...

    27 May 2014 | Michael Carter
  • Tenofovir HIV PrEP causes no long-term harm to kidneys

    HIV pre-exposure prophylaxis (PrEP) with tenofovir is associated with mild disturbances in kidney function that resolve when treatment is stopped, investigators report in the online edition of Clinical Infectious Diseases. The study, in Thailand, involved people who inject drugs who ...

    21 May 2014 | Michael Carter
  • New US guidelines recommend PrEP

    The US Centers for Disease Control and Prevention (CDC) today released new guidelines recommending that pre-exposure prophylaxis (PrEP) should be considered for anyone HIV-negative who:Is in an ongoing sexual relationship with a partner living with HIV.Is ...

    14 May 2014 | Gus Cairns
  • Daily dosing key to the efficacy of tenofovir-based HIV PrEP

    Good adherence is key to the efficacy of tenofovir-based HIV pre-exposure prophylaxis (PrEP), according to research published in the online edition of the Journal of Acquired Immune Deficiency Syndromes. Plasma-concentrations of tenofovir that were consistent with daily dosing reduced the ...

    14 May 2014 | Michael Carter
  • No significant risk of resistance if HIV infection occurs during use of Truvada PrEP

    Treatment with pre-exposure prophylaxis (PrEP) does not involve a significant risk of HIV drug resistance should seroconversion occur, results from the iPrEx study published in the online edition of the Journal of Infectious Diseases demonstrate. The only cases of drug resistance ...

    13 May 2014 | Michael Carter
More news

PrEP news selected from other sources

  • HIV, HCV and TB Pipeline Report

    Drugs, diagnostics, vaccines, preventive technologies, research towards a cure, and immune-based and gene therapies in development.

    21 July 2014 | Treatment Action Group & i-Base
  • Declining investment could slow research and rollout of new HIV prevention options

    Investment in HIV prevention research fell US$50 million, or 4 percent, to US$1.26 billion in 2013, due to declining investments by the United States and European government donors, changes in the international development landscape and changes in the pipeline of HIV prevention products in various stages of development and implementation, according to a new report from the HIV Vaccines and Microbicides Resource Tracking Working Group.

    20 July 2014 | HIV Vaccines and Microbicides Resource Tracking Working Group press release
  • HIV Prevention in Clinical Care Settings - 2014 Recommendations of the International Antiviral Society–USA Panel

    In an innovative approach to HIV prevention, an interdisciplinary group of experts has come together for the first time to lay out a framework of best practices to optimize the role of the clinician in achieving an AIDS-free generation.

    19 July 2014 | Journal of the American Medical Association
  • New Momentum on PrEP, But Critical Needs Are Overlooked

    Oral PrEP should be integrated into comprehensive, high-impact prevention programs for all people at risk internationally, with particular attention to key populations but also for young women and married women who continue to bear the brunt of the epidemic. WHO needs to quickly issue guidance on PrEP for all of the populations that can benefit.

    19 July 2014 | Huffington Post
  • Is Truvada, the Pill to Prevent H.I.V., 99 Percent Effective? Don’t Be So Sure

    All of the H.I.V. researchers and experts I spoke with for this article agree that Truvada works well to prevent H.I.V. infection and that its effectiveness is closely tied to frequency of dosing. But they did not all agree about how much to rely on the 99 percent estimate.

    17 July 2014 | New York Times
  • WHO: No, Not All Gay Men Need to Take Antiretroviral Drugs

    A new recommendation from the World Health Organization about who should take drugs to prevent HIV is causing confusion and controversy nationwide.

    17 July 2014 | Healthline
  • I'm an HIV Physician. And I'm Starting PrEP.

    I am tired of being scared, so I am starting on PrEP (pre-exposure prophylaxis). I hope that by sharing my story I may help others make decisions about protecting their own health.

    16 July 2014 | The Body
  • Should All Gay and Bisexual Men Take PrEP?

    Did the World Health Organization (WHO) really declare that all gay men should take Pre-exposure Prophylaxis?

    15 July 2014 | Huffington Post
  • The new pill that could revolutionize gay life is reawakening old arguments

    For the past several years, the conversation about gay life has been, to a large degree, a conversation about gay marriage. This summer—on social media, on Fire Island, at the Christopher Street pier, and in certain cohorts around the ­country—what many gay men are talking about among themselves is Truvada. And what’s surprising them is how fraught the conversation can be.

    14 July 2014 | New York magazine
  • Pill to Prevent H.I.V. Gets a Prominent Backer: Andrew Cuomo

    On Sunday, Gov. Andrew Cuomo announced an ambitious goal: Ending the AIDS epidemic in New York State by 2020.

    04 July 2014 | New York Times
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.